Featured Research

from universities, journals, and other organizations

Doubling of deaths among sick moms-to-be amid poor evidence on drug safety in pregnancy

Date:
June 12, 2013
Source:
BMJ-British Medical Journal
Summary:
The lack of hard data on the safety and effectiveness of a wide range of drugs in pregnancy has hindered the treatment of pregnant women, contributing to a doubling of deaths amongst mums-to-be with an underlying health problem over the past 20 years, argues a new editorial.

The lack of hard data on the safety and effectiveness of a wide range of drugs in pregnancy has hindered the treatment of pregnant women, contributing to a doubling of deaths amongst mums-to-be with an underlying health problem over the past 20 years, argues an editorial in the Drug and Therapeutics Bulletin (DTB).

It's time to include pregnant women in drug trials so that they can get the medical treatment they need, says DTB.

In the absence of reliable information on the pros and cons of treatment during pregnancy, and haunted by the spectre of thalidomide, doctors are reluctant to prescribe, while pregnant women are wary of taking drugs that might harm their developing baby, contends the editorial.

Yet an estimated one in 10 mums-to-be has a long term condition that requires medication, while around four out of 10 develop new health problems during their pregnancy.

And it's going to get worse, prompted by the increasing trend for older age at childbirth and the expanding girth of the nation, both of which are pushing up the numbers of women requiring drug treatment during their pregnancy, warns the editorial.

Some 4% of women who gave birth in England and Wales in 2011 were aged 40 and over -- compared with just 1% a decade earlier -- while almost one in five women of childbearing age were obese in 2008.

But the unwillingness to prescribe and be treated can be fatal, warns DTB. The number of "indirect" deaths among new mums in the UK -- where pregnancy worsens a new or pre-existing medical or mental health problem -- has almost doubled over the past 20 years, and now exceeds deaths directly caused by pregnancy by 50%, it says.

It's rare for a drug company or research team to include pregnant women in drug trials, says DTB. All too often they are put off by the complex ethical issues involved.

Yet equally, it could be argued that it is unethical not to include them in drug trials, especially as side effects can take many years to emerge, it says, citing sodium valproate, the anti-epileptic drug, as a case in point.

["This] was hailed as a wonder anticonvulsant in the 1960s, linked with neural tube defects in the 1980s, and associated with adverse neurodevelopmental effects in the offspring with third trimester exposure in the 2000s," it notes.

It's time to emulate the way in which children's medicines are now being investigated properly, says DTB, which calls on industry and regulators to include women in drug trials.

"With increasing awareness that the intrauterine environment is important for the long term development of children, it is ever more important that those involved in drug development and trials look for ways to safely involved pregnant women rather than automatically exclude them," contends the editorial.

"Pregnancy is a natural state that has been ignored by the pharmaceutical industry for too long," it concludes.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Editorial. Prescribing in pregnancy--therapeutic discrimination? Drug and Therapeutics Bulletin, 2013;51:61 DOI: 10.1136/dtb.2013.6.0182

Cite This Page:

BMJ-British Medical Journal. "Doubling of deaths among sick moms-to-be amid poor evidence on drug safety in pregnancy." ScienceDaily. ScienceDaily, 12 June 2013. <www.sciencedaily.com/releases/2013/06/130612224224.htm>.
BMJ-British Medical Journal. (2013, June 12). Doubling of deaths among sick moms-to-be amid poor evidence on drug safety in pregnancy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/06/130612224224.htm
BMJ-British Medical Journal. "Doubling of deaths among sick moms-to-be amid poor evidence on drug safety in pregnancy." ScienceDaily. www.sciencedaily.com/releases/2013/06/130612224224.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins